To sign up to the Graham Hancock newsletter mailing list, please click here.
A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.
Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose.
Back to Previous...
Go to News Desk...
Enjoy the newsdesk? Please tell others about it:Tweet
Dedicated Servers and Cloud Servers by Gigenet. Invert Colour Scheme / Default